The influence of metoprolol in patients with sepsis-induced cardiomyopathy: A retrospective study

Wenna Ning; Yaou Chen; Jian Lu; Jinwei Zhu; Longgang Li

doi:10.15537/smj.2023.44.10.20230149

References

1.↵
1. Singer M,
2. Deutschman CS,
3. Seymour CW,
4. Shankar-Hari M,
5. Annane D,
6. Bauer M, et al.
The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 2016; 315: 801–810.
OpenUrl CrossRef PubMed
2.
1. Shankar-Hari M,
2. Phillips GS,
3. Levy ML,
4. Seymour CW,
5. Liu VX,
6. Deutschman CS, et al.
Developing a new definition and assessing new clinical criteria for septic shock: for the third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 2016; 315: 775–787.
OpenUrl CrossRef PubMed
3.↵
1. Seymour CW,
2. Liu VX,
3. Iwashyna TJ,
4. Brunkhorst FM,
5. Rea TD,
6. Scherag A, et al.
assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 2016; 315: 762–774.
OpenUrl CrossRef PubMed
4.↵
1. Liang YW,
2. Zhu YF,
3. Zhang R,
4. Zhang M,
5. Ye XL,
6. Wei JR.
Incidence, prognosis, and risk factors of sepsis-induced cardiomyopathy. World J Clin Cases 2021; 9: 9452–9468.
OpenUrl
5.↵
1. L’Heureux M,
2. Sternberg M,
3. Brath L,
4. Turlington J,
5. Kashiouris MG.
Sepsis-induced cardiomyopathy: a comprehensive review. Curr Cardiol Rep 2020; 22: 35.
OpenUrl
6.↵
1. Suzuki T,
2. Suzuki Y,
3. Okuda J,
4. Kurazumi T,
5. Suhara T,
6. Ueda T, et al.
Sepsis-induced cardiac dysfunction and β-adrenergic blockade therapy for sepsis. J Intensive Care 2017; 5: 22.
OpenUrl
7.↵
1. McLean AS,
2. Taccone FS,
3. Vieillard-Baron A.
Beta-blockers in septic shock to optimize hemodynamics? No. Intensive Care Med 2016; 42: 1610–1612.
OpenUrl
8.↵
1. Hosokawa K,
2. Su F,
3. Taccone FS,
4. Post EH,
5. Pereira AJ,
6. Herpain A, et al.
Esmolol administration to control tachycardia in an ovine model of peritonitis. Anesth Analg 2017; 125: 1952–1959.
OpenUrl
9.↵
1. Lesur O,
2. Delile E,
3. Asfar P,
4. Radermacher P.
Hemodynamic support in the early phase of septic shock: a review of challenges and unanswered questions. Ann Intensive Care 2018; 8: 102.
OpenUrl PubMed
10.↵
1. Singer M.
Catecholamine treatment for shock--equally good or bad? Lancet 2007; 370: 636–637.
OpenUrl CrossRef PubMed Web of Science
11.↵
1. Li J,
2. Sun W,
3. Guo Y,
4. Ren Y,
5. Li Y,
6. Yang Z.
Prognosis of β-adrenergic blockade therapy on septic shock and sepsis: a systematic review and meta-analysis of randomized controlled studies. Cytokine 2020; 126: 154916.
OpenUrl
12.↵
1. Lee YR,
2. Seth MS,
3. Soney D,
4. Dai H.
Benefits of beta-blockade in sepsis and septic shock: a systematic review. Clin Drug Investig 2019; 39: 429–440.
OpenUrl
13.↵
1. Tan K,
2. Harazim M,
3. Tang B,
4. Mclean A,
5. Nalos M.
The association between premorbid beta blocker exposure and mortality in sepsis-a systematic review. Crit Care 2019; 23: 298.
OpenUrl PubMed
14.↵
1. Huang P,
2. Zheng X,
3. Liu Z,
4. Fang X.
The efficacy and safety of esmolol for septic shock: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol 2021; 12: 682232.
OpenUrl
15.↵
1. Liu H,
2. Ding XF,
3. Zhang SG,
4. Wang HX,
5. Luo YG,
6. Duan XG, et al.
[Effect of esmolol in septic shock patients with tachycardia: a randomized clinical trial]. Zhonghua Yi Xue Za Zhi 2019; 99: 1317–1322. [In Chinese]
OpenUrl
16.↵
1. Brown SM,
2. Beesley SJ,
3. Lanspa MJ,
4. Grissom CK,
5. Wilson EL,
6. Parikh SM, et al.
Esmolol infusion in patients with septic shock and tachycardia: a prospective, single-arm, feasibility study. Pilot Feasibility Stud 2018; 4: 132.
OpenUrl
17.
1. Morelli A,
2. Singer M,
3. Ranieri VM,
4. D’Egidio A,
5. Mascia L,
6. Orecchioni A, et al.
Heart rate reduction with esmolol is associated with improved arterial elastance in patients with septic shock: a prospective observational study. Intensive Care Med 2016; 42: 1528–1534.
OpenUrl
18.
1. Du W,
2. Wang XT,
3. Long Y,
4. Liu DW.
Efficacy and safety of esmolol in treatment of patients with septic shock. Chin Med J (Engl) 2016; 129: 1658–1665.
OpenUrl
19.↵
1. Xinqiang L,
2. Weiping H,
3. Miaoyun W,
4. Wenxin Z,
5. Wenqiang J,
6. Shenglong C, et al.
[Esmolol improves clinical outcome and tissue oxygen metabolism in patients with septic shock through controlling heart rate]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2015; 27: 759–763. [In Chinese]
OpenUrl
20.↵
1. Xinyuan Li,
2. Caijun Wu,
3. Nan Guo,
4. Shangshang Jiang,
5. Yuefeng Fu,
6. Zhihua Han
. The research progress of sepsis cardiomyopathy. Chin J TCM WM Crit Care 2019; 26: 372–377.
OpenUrl
21.↵
1. Arita Y,
2. Segawa T,
3. Yamamoto S,
4. Hasegawa S.
Landiolol is effective for the treatment of tachycardia-induced cardiogenic shock in patients during septic shock therapy. BMJ Case Rep 2017; 2017: bcr2017222268.
OpenUrl PubMed
22.↵
1. Jing Zhang,
2. Chun Chen,
3. Yi Liu,
4. Yi Yang,
5. Xiaolei Yang,
6. Jin Yang
. Benefits of esmolol in adults with sepsis and septic shock: An updated meta-analysis of randomized controlled trials. Medicine (Baltimore) 2022; 101: e29820.
OpenUrl
23.↵
1. Tan K,
2. Harazim M,
3. Simpson A,
4. Tan YC,
5. Gunawan G,
6. Robledo KP, et al.
Association between premorbid beta-blocker exposure and sepsis outcomes-the beta-blockers in European and Australian/American septic patients (BEAST) study. Crit Care Med 2021; 49: 1493–1503.
OpenUrl
24.↵
1. Xiuxiu Lv,
2. Huadong Wang
. Pathophysiology of sepsis-induced myocardial. Mil Med Res 2016; 3: 30.
OpenUrl
25.↵
1. Hollenberg SM,
2. Singer M.
Pathophysiology of sepsis-induced cardiomyopathy. Nat Rev Cardiol 2021; 18: 424–434.
OpenUrl CrossRef PubMed
26.↵
1. Lesur O,
2. Delile E,
3. Asfar P,
4. Radermacher P.
Hemodynamic support in the early phase of septic shock: a review of challenges and unanswered questions. Ann Intensive Care 2018; 8: 102.
OpenUrl PubMed
27.↵
1. Fuchs C,
2. Wauschkuhn S,
3. Scheer C,
4. Vollmer M,
5. Meissner K,
6. Kuhn SO, et al.
Continuing chronic beta-blockade in the acute phase of severe sepsis and septic shock is associated with decreased mortality rates up to 90 days. Br J Anaesth 2017; 119: 616–625.
OpenUrl
28.↵
1. Kimmoun A,
2. Louis H,
3. Al Kattani N,
4. Delemazure J,
5. Dessales N,
6. Wei C, et al.
β1-adrenergic inhibition improves cardiac and vascular function in experimental septic shock. Crit Care Med 2015; 43: e332–e340.
OpenUrl
29.↵
1. Van Loon LM,
2. Van der Hoeven JG,
3. Lemson J.
Hemodynamic response to β-blockers in severe sepsis and septic shock: a review of current literature. J Crit Care 2019; 50: 138–143.
OpenUrl
30.↵
1. Hernández G,
2. Tapia P,
3. Alegría L,
4. Soto D,
5. Luengo C,
6. Gomez J, et al.
Effects of dexmedetomidine and esmolol on systemic hemodynamics and exogenous lactate clearance in early experimental septic shock. Crit Care 2016; 20: 234
OpenUrl
31.
1. Wang Z,
2. Wu Q,
3. Nie X,
4. Guo J,
5. Yang C.
Combination therapy with milrinone and esmolol for heart protection in patients with severe sepsis: a prospective, randomized trial. Clin Drug Investig 2015; 35: 707–716.
OpenUrl

In this issue

Download PDF

Email Article

Citation Tools

Bookmark this article

Cited By...

No citing articles found.

Google Scholar

More in this TOC Section

Show more Original Article

Keywords

[1] 1.↵
Singer M,
Deutschman CS,
Seymour CW,
Shankar-Hari M,
Annane D,
Bauer M, et al.
The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 2016; 315: 801–810.
OpenUrl CrossRef PubMed

[2] Singer M,

[3] Deutschman CS,

[4] Seymour CW,

[5] Shankar-Hari M,

[6] Annane D,

[7] Bauer M, et al.

[8] 2.
Shankar-Hari M,
Phillips GS,
Levy ML,
Seymour CW,
Liu VX,
Deutschman CS, et al.
Developing a new definition and assessing new clinical criteria for septic shock: for the third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 2016; 315: 775–787.
OpenUrl CrossRef PubMed

[9] Shankar-Hari M,

[10] Phillips GS,

[11] Levy ML,

[12] Seymour CW,

[13] Liu VX,

[14] Deutschman CS, et al.

[15] 3.↵
Seymour CW,
Liu VX,
Iwashyna TJ,
Brunkhorst FM,
Rea TD,
Scherag A, et al.
assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 2016; 315: 762–774.
OpenUrl CrossRef PubMed

[16] Seymour CW,

[17] Liu VX,

[18] Iwashyna TJ,

[19] Brunkhorst FM,

[20] Rea TD,

[21] Scherag A, et al.

[22] 4.↵
Liang YW,
Zhu YF,
Zhang R,
Zhang M,
Ye XL,
Wei JR.
Incidence, prognosis, and risk factors of sepsis-induced cardiomyopathy. World J Clin Cases 2021; 9: 9452–9468.
OpenUrl

[23] Liang YW,

[24] Zhu YF,

[25] Zhang R,

[26] Zhang M,

[27] Ye XL,

[28] Wei JR.

[29] 5.↵
L’Heureux M,
Sternberg M,
Brath L,
Turlington J,
Kashiouris MG.
Sepsis-induced cardiomyopathy: a comprehensive review. Curr Cardiol Rep 2020; 22: 35.
OpenUrl

[30] L’Heureux M,

[31] Sternberg M,

[32] Brath L,

[33] Turlington J,

[34] Kashiouris MG.

[35] 6.↵
Suzuki T,
Suzuki Y,
Okuda J,
Kurazumi T,
Suhara T,
Ueda T, et al.
Sepsis-induced cardiac dysfunction and β-adrenergic blockade therapy for sepsis. J Intensive Care 2017; 5: 22.
OpenUrl

[36] Suzuki T,

[37] Suzuki Y,

[38] Okuda J,

[39] Kurazumi T,

[40] Suhara T,

[41] Ueda T, et al.

[42] 7.↵
McLean AS,
Taccone FS,
Vieillard-Baron A.
Beta-blockers in septic shock to optimize hemodynamics? No. Intensive Care Med 2016; 42: 1610–1612.
OpenUrl

[43] McLean AS,

[44] Taccone FS,

[45] Vieillard-Baron A.

[46] 8.↵
Hosokawa K,
Su F,
Taccone FS,
Post EH,
Pereira AJ,
Herpain A, et al.
Esmolol administration to control tachycardia in an ovine model of peritonitis. Anesth Analg 2017; 125: 1952–1959.
OpenUrl

[47] Hosokawa K,

[48] Su F,

[49] Taccone FS,

[50] Post EH,

[51] Pereira AJ,

[52] Herpain A, et al.

[53] 9.↵
Lesur O,
Delile E,
Asfar P,
Radermacher P.
Hemodynamic support in the early phase of septic shock: a review of challenges and unanswered questions. Ann Intensive Care 2018; 8: 102.
OpenUrl PubMed

[54] Lesur O,

[55] Delile E,

[56] Asfar P,

[57] Radermacher P.

[58] 10.↵
Singer M.
Catecholamine treatment for shock--equally good or bad? Lancet 2007; 370: 636–637.
OpenUrl CrossRef PubMed Web of Science

[59] Singer M.

[60] 11.↵
Li J,
Sun W,
Guo Y,
Ren Y,
Li Y,
Yang Z.
Prognosis of β-adrenergic blockade therapy on septic shock and sepsis: a systematic review and meta-analysis of randomized controlled studies. Cytokine 2020; 126: 154916.
OpenUrl

[61] Li J,

[62] Sun W,

[63] Guo Y,

[64] Ren Y,

[65] Li Y,

[66] Yang Z.

[67] 12.↵
Lee YR,
Seth MS,
Soney D,
Dai H.
Benefits of beta-blockade in sepsis and septic shock: a systematic review. Clin Drug Investig 2019; 39: 429–440.
OpenUrl

[68] Lee YR,

[69] Seth MS,

[70] Soney D,

[71] Dai H.

[72] 13.↵
Tan K,
Harazim M,
Tang B,
Mclean A,
Nalos M.
The association between premorbid beta blocker exposure and mortality in sepsis-a systematic review. Crit Care 2019; 23: 298.
OpenUrl PubMed

[73] Tan K,

[74] Harazim M,

[75] Tang B,

[76] Mclean A,

[77] Nalos M.

[78] 14.↵
Huang P,
Zheng X,
Liu Z,
Fang X.
The efficacy and safety of esmolol for septic shock: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol 2021; 12: 682232.
OpenUrl

[79] Huang P,

[80] Zheng X,

[81] Liu Z,

[82] Fang X.

[83] 15.↵
Liu H,
Ding XF,
Zhang SG,
Wang HX,
Luo YG,
Duan XG, et al.
[Effect of esmolol in septic shock patients with tachycardia: a randomized clinical trial]. Zhonghua Yi Xue Za Zhi 2019; 99: 1317–1322. [In Chinese]
OpenUrl

[84] Liu H,

[85] Ding XF,

[86] Zhang SG,

[87] Wang HX,

[88] Luo YG,

[89] Duan XG, et al.

[90] 16.↵
Brown SM,
Beesley SJ,
Lanspa MJ,
Grissom CK,
Wilson EL,
Parikh SM, et al.
Esmolol infusion in patients with septic shock and tachycardia: a prospective, single-arm, feasibility study. Pilot Feasibility Stud 2018; 4: 132.
OpenUrl

[91] Brown SM,

[92] Beesley SJ,

[93] Lanspa MJ,

[94] Grissom CK,

[95] Wilson EL,

[96] Parikh SM, et al.

[97] 17.
Morelli A,
Singer M,
Ranieri VM,
D’Egidio A,
Mascia L,
Orecchioni A, et al.
Heart rate reduction with esmolol is associated with improved arterial elastance in patients with septic shock: a prospective observational study. Intensive Care Med 2016; 42: 1528–1534.
OpenUrl

[98] Morelli A,

[99] Singer M,

[100] Ranieri VM,

[101] D’Egidio A,

[102] Mascia L,

[103] Orecchioni A, et al.

[104] 18.
Du W,
Wang XT,
Long Y,
Liu DW.
Efficacy and safety of esmolol in treatment of patients with septic shock. Chin Med J (Engl) 2016; 129: 1658–1665.
OpenUrl

[105] Du W,

[106] Wang XT,

[107] Long Y,

[108] Liu DW.

[109] 19.↵
Xinqiang L,
Weiping H,
Miaoyun W,
Wenxin Z,
Wenqiang J,
Shenglong C, et al.
[Esmolol improves clinical outcome and tissue oxygen metabolism in patients with septic shock through controlling heart rate]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2015; 27: 759–763. [In Chinese]
OpenUrl

[110] Xinqiang L,

[111] Weiping H,

[112] Miaoyun W,

[113] Wenxin Z,

[114] Wenqiang J,

[115] Shenglong C, et al.

[116] 20.↵
Xinyuan Li,
Caijun Wu,
Nan Guo,
Shangshang Jiang,
Yuefeng Fu,
Zhihua Han
. The research progress of sepsis cardiomyopathy. Chin J TCM WM Crit Care 2019; 26: 372–377.
OpenUrl

[117] Xinyuan Li,

[118] Caijun Wu,

[119] Nan Guo,

[120] Shangshang Jiang,

[121] Yuefeng Fu,

[122] Zhihua Han

[123] 21.↵
Arita Y,
Segawa T,
Yamamoto S,
Hasegawa S.
Landiolol is effective for the treatment of tachycardia-induced cardiogenic shock in patients during septic shock therapy. BMJ Case Rep 2017; 2017: bcr2017222268.
OpenUrl PubMed

[124] Arita Y,

[125] Segawa T,

[126] Yamamoto S,

[127] Hasegawa S.

[128] 22.↵
Jing Zhang,
Chun Chen,
Yi Liu,
Yi Yang,
Xiaolei Yang,
Jin Yang
. Benefits of esmolol in adults with sepsis and septic shock: An updated meta-analysis of randomized controlled trials. Medicine (Baltimore) 2022; 101: e29820.
OpenUrl

[129] Jing Zhang,

[130] Chun Chen,

[131] Yi Liu,

[132] Yi Yang,

[133] Xiaolei Yang,

[134] Jin Yang

[135] 23.↵
Tan K,
Harazim M,
Simpson A,
Tan YC,
Gunawan G,
Robledo KP, et al.
Association between premorbid beta-blocker exposure and sepsis outcomes-the beta-blockers in European and Australian/American septic patients (BEAST) study. Crit Care Med 2021; 49: 1493–1503.
OpenUrl

[136] Tan K,

[137] Harazim M,

[138] Simpson A,

[139] Tan YC,

[140] Gunawan G,

[141] Robledo KP, et al.

[142] 24.↵
Xiuxiu Lv,
Huadong Wang
. Pathophysiology of sepsis-induced myocardial. Mil Med Res 2016; 3: 30.
OpenUrl

[143] Xiuxiu Lv,

[144] Huadong Wang

[145] 25.↵
Hollenberg SM,
Singer M.
Pathophysiology of sepsis-induced cardiomyopathy. Nat Rev Cardiol 2021; 18: 424–434.
OpenUrl CrossRef PubMed

[146] Hollenberg SM,

[147] Singer M.

[148] 26.↵
Lesur O,
Delile E,
Asfar P,
Radermacher P.
Hemodynamic support in the early phase of septic shock: a review of challenges and unanswered questions. Ann Intensive Care 2018; 8: 102.
OpenUrl PubMed

[149] Lesur O,

[150] Delile E,

[151] Asfar P,

[152] Radermacher P.

[153] 27.↵
Fuchs C,
Wauschkuhn S,
Scheer C,
Vollmer M,
Meissner K,
Kuhn SO, et al.
Continuing chronic beta-blockade in the acute phase of severe sepsis and septic shock is associated with decreased mortality rates up to 90 days. Br J Anaesth 2017; 119: 616–625.
OpenUrl

[154] Fuchs C,

[155] Wauschkuhn S,

[156] Scheer C,

[157] Vollmer M,

[158] Meissner K,

[159] Kuhn SO, et al.

[160] 28.↵
Kimmoun A,
Louis H,
Al Kattani N,
Delemazure J,
Dessales N,
Wei C, et al.
β1-adrenergic inhibition improves cardiac and vascular function in experimental septic shock. Crit Care Med 2015; 43: e332–e340.
OpenUrl

[161] Kimmoun A,

[162] Louis H,

[163] Al Kattani N,

[164] Delemazure J,

[165] Dessales N,

[166] Wei C, et al.

[167] 29.↵
Van Loon LM,
Van der Hoeven JG,
Lemson J.
Hemodynamic response to β-blockers in severe sepsis and septic shock: a review of current literature. J Crit Care 2019; 50: 138–143.
OpenUrl

[168] Van Loon LM,

[169] Van der Hoeven JG,

[170] Lemson J.

[171] 30.↵
Hernández G,
Tapia P,
Alegría L,
Soto D,
Luengo C,
Gomez J, et al.
Effects of dexmedetomidine and esmolol on systemic hemodynamics and exogenous lactate clearance in early experimental septic shock. Crit Care 2016; 20: 234
OpenUrl

[172] Hernández G,

[173] Tapia P,

[174] Alegría L,

[175] Soto D,

[176] Luengo C,

[177] Gomez J, et al.

[178] 31.
Wang Z,
Wu Q,
Nie X,
Guo J,
Yang C.
Combination therapy with milrinone and esmolol for heart protection in patients with severe sepsis: a prospective, randomized trial. Clin Drug Investig 2015; 35: 707–716.
OpenUrl

[179] Wang Z,

[180] Wu Q,

[181] Nie X,

[182] Guo J,

[183] Yang C.

Main menu

User menu

Search

The influence of metoprolol in patients with sepsis-induced cardiomyopathy

A retrospective study

References

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords

CONTENT

JOURNAL

AUTHORS

Main menu

User menu

Search

The influence of metoprolol in patients with sepsis-induced cardiomyopathy

A retrospective study

References

In this issue

Citation Manager Formats

Jump to section

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords

CONTENT

JOURNAL

AUTHORS